Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The impact of SARS-CoV-2 vaccines on antibody responses in the general population in the United Kingdom

Jia Wei, Nicole Stoesser, Philippa C. Matthews, Ruth Studley, Iain Bell, John I Bell, John N Newton, Jeremy Farrar, Ian Diamond, Emma Rourke, Alison Howarth, Brian D. Marsden, Sarah Hoosdally, E Yvonne Jones, David I Stuart, Derrick W .Crook, Tim E. A. Peto, Koen B. Pouwels, David W. Eyre, A. Sarah Walker, COVID-19 Infection Survey team
doi: https://doi.org/10.1101/2021.04.22.21255911
Jia Wei
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
2Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicole Stoesser
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
3The National Institute for Health Research Health Protection Research Unit in Healthcare Associated, Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK
4The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
5Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippa C. Matthews
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
5Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth Studley
6Office for National Statistics, Newport, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iain Bell
6Office for National Statistics, Newport, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John I Bell
7Office of the Regius Professor of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John N Newton
8Health Improvement Directorate, Public Health England, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy Farrar
9Wellcome Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Diamond
6Office for National Statistics, Newport, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma Rourke
6Office for National Statistics, Newport, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alison Howarth
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
5Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian D. Marsden
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
10Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Hoosdally
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E Yvonne Jones
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David I Stuart
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derrick W .Crook
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
3The National Institute for Health Research Health Protection Research Unit in Healthcare Associated, Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK
4The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
5Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim E. A. Peto
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
3The National Institute for Health Research Health Protection Research Unit in Healthcare Associated, Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK
4The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
5Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koen B. Pouwels
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
2Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK
3The National Institute for Health Research Health Protection Research Unit in Healthcare Associated, Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK
11Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David W. Eyre
2Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK
3The National Institute for Health Research Health Protection Research Unit in Healthcare Associated, Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK
4The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
5Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: david.eyre@bdi.ox.ac.uk
A. Sarah Walker
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
2Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK
3The National Institute for Health Research Health Protection Research Unit in Healthcare Associated, Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK
12MRC Clinical Trials Unit at UCL, UCL, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Real-world data on antibody response post-vaccination in the general population are limited. 45,965 adults in the UK’s national COVID-19 Infection Survey receiving Pfizer-BioNTech or Oxford-AstraZeneca vaccines had 111,360 anti-spike IgG measurements. Without prior infection, seroconversion rates and quantitative antibody levels post single dose were lower in older individuals, especially >60y. Two doses achieved high responses across all ages, particularly increasing seroconversion in older people, to similar levels to those achieved after prior infection followed by a single dose. Antibody levels rose more slowly and to lower levels with Oxford-AstraZeneca vs Pfizer-BioNTech, but waned following a single Pfizer-BioNTech dose. Latent class models identified four responder phenotypes: older people, males, and those having long-term health conditions were more commonly ‘low responders’. Where supplies are limited, vaccines should be prioritised for those not previously infected, and second doses to individuals >60y. Further data on the relationship between vaccine-mediated protection and antibody responses are needed.

Competing Interest Statement

DWE declares lecture fees from Gilead, outside the submitted work. No other author has a conflict of interest to declare.

Clinical Trial

ISRCTN21086382

Clinical Protocols

https://www.ndm.ox.ac.uk/covid-19/covid-19-infection-survey/protocol-and-information-sheets

Funding Statement

This study is funded by the Department of Health and Social Care with in-kind support from the Welsh Government, the Department of Health on behalf of the Northern Ireland Government and the Scottish Government. ASW, TEAP, NS, DE, KBP are supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with Public Health England (PHE) (NIHR200915). ASW and TEAP are also supported by the NIHR Oxford Biomedical Research Centre. KBP is also supported by the Huo Family Foundation. ASW is also supported by core support from the Medical Research Council UK to the MRC Clinical Trials Unit [MC_UU_12023/22] and is an NIHR Senior Investigator. PCM is funded by Wellcome (intermediate fellowship, grant ref 110110/Z/15/Z) and holds an NIHR Oxford BRC Senior Fellowship award. DWE is supported by a Robertson Fellowship and an NIHR Oxford BRC Senior Fellowship. The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, Department of Health, or PHE.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study received ethical approval from the South Central Berkshire B Research Ethics Committee (20/SC/0195).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • See Acknowledgements for the Coronavirus Infection Survey team

Data Availability

Data are still being collected for the COVID-19 Infection Survey. De-identified study data are available for access by accredited researchers in the ONS Secure Research Service (SRS) for accredited research purposes under part 5, chapter 5 of the Digital Economy Act 2017. For further information about accreditation, contact Research.Support@ons.gov.uk or visit the SRS website.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted April 23, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The impact of SARS-CoV-2 vaccines on antibody responses in the general population in the United Kingdom
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The impact of SARS-CoV-2 vaccines on antibody responses in the general population in the United Kingdom
Jia Wei, Nicole Stoesser, Philippa C. Matthews, Ruth Studley, Iain Bell, John I Bell, John N Newton, Jeremy Farrar, Ian Diamond, Emma Rourke, Alison Howarth, Brian D. Marsden, Sarah Hoosdally, E Yvonne Jones, David I Stuart, Derrick W .Crook, Tim E. A. Peto, Koen B. Pouwels, David W. Eyre, A. Sarah Walker, COVID-19 Infection Survey team
medRxiv 2021.04.22.21255911; doi: https://doi.org/10.1101/2021.04.22.21255911
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
The impact of SARS-CoV-2 vaccines on antibody responses in the general population in the United Kingdom
Jia Wei, Nicole Stoesser, Philippa C. Matthews, Ruth Studley, Iain Bell, John I Bell, John N Newton, Jeremy Farrar, Ian Diamond, Emma Rourke, Alison Howarth, Brian D. Marsden, Sarah Hoosdally, E Yvonne Jones, David I Stuart, Derrick W .Crook, Tim E. A. Peto, Koen B. Pouwels, David W. Eyre, A. Sarah Walker, COVID-19 Infection Survey team
medRxiv 2021.04.22.21255911; doi: https://doi.org/10.1101/2021.04.22.21255911

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (270)
  • Allergy and Immunology (552)
  • Anesthesia (135)
  • Cardiovascular Medicine (1757)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (658)
  • Epidemiology (10796)
  • Forensic Medicine (8)
  • Gastroenterology (589)
  • Genetic and Genomic Medicine (2946)
  • Geriatric Medicine (287)
  • Health Economics (534)
  • Health Informatics (1927)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (291)
  • HIV/AIDS (630)
  • Infectious Diseases (except HIV/AIDS) (12515)
  • Intensive Care and Critical Care Medicine (688)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2798)
  • Nursing (151)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1463)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (866)
  • Pharmacology and Therapeutics (366)
  • Primary Care Research (337)
  • Psychiatry and Clinical Psychology (2639)
  • Public and Global Health (5363)
  • Radiology and Imaging (1011)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (726)
  • Rheumatology (330)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (150)
  • Urology (125)